|Articles|January 23, 2023
At-line Spent Media Analysis using the REBEL to Optimize a CHO mAb Fed-Batch Process
Author(s)908 Devices
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Regulatory Uncertainty Surfaces as FDA Blames COVID Vaccines for 10 Child Deaths
2
New Draft Guidance Highlights FDA Push Toward Human-Relevant Safety Models
3
Implementing Automation and Flexible Design for Allogeneic Manufacturing
4
Rentschler–Coriolis Partnership Reflects Demand for Connected Biopharma Workflows
5
